Caladrius Biosciences' Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement With Roche To Evaluate CEND-1 In Combination With Immunotherapy To Treat Pancreatic Cancer

Author: Benzinga Newsdesk | August 10, 2022 08:03am

Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company") and Cend Therapeutics, Inc. ("Cend"), today announced Cend's execution of a collaboration agreement with F. Hoffmann-La Roche Ltd. ("Roche") to evaluate Cend's lead investigational drug, CEND-1, in combination with atezolizumab (Tecentriq®), Roche's PD-L1 checkpoint inhibitor, along with standard-of-care chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma ("mPDAC"). Under the terms of the agreement, Roche will be responsible for operational management of the trial while Cend and Roche share equally in the costs of the CEND-1 treatment arms in the study.

Posted In: CLBS